Literature DB >> 1591725

Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.

A Basu1, J S Lazo.   

Abstract

Bryostatins are an important class of protein kinase C (PKC) activators. We have investigated the effect of bryostatin 1 on the antiproliferative activity of cis-diamminedichloroplatinum(II) (CP). A 24-h pretreatment of HeLa cells with 1 nM bryostatin 1 increased cellular sensitivity to CP by 4-fold. The effect of bryostatin 1 on the IC50 of CP (concentration of drug required to inhibit cell proliferation by 50%) was concentration-dependent and biphasic; the maximum effect of bryostatin 1 was seen with 1 nM, but higher concentrations of bryostatin 1 (greater than or equal to 10 nM) produced less CP sensitization. Although bryostatin 1 and phorbol esters caused an equivalent stimulation of HeLa cell PKC in cell-free systems, bryostatin 1 was less effective than phorbol esters in sensitizing cells to CP. Additionally, higher concentrations of bryostatin 1 (greater than or equal to 10 nM) antagonized CP sensitization by phorbol esters. Bryostatin 1 was even more potent than 12-O-tetradecanoylphorbol-13-acetate in inducing PKC down-regulation, and the maximum down-regulation was achieved with 10 nM bryostatin 1. Bryostatin 1 also increased cellular sensitivity to a CP analogue, cis-dichloro(ethylenediamine)platinum(II). A 24-h pretreatment with 1 nM bryostatin 1 increased cellular cis-[3H]DEP by 60%. The concentration- and time-dependent enhancement in CP sensitivity by bryostatin 1 was related to the increase in cis-[3H]DEP level. Thus, cellular accumulation of CP may be regulated by a PKC-dependent phosphorylation event.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1591725

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.

Authors:  Deborah K Armstrong; John A Blessing; Janet Rader; Joel I Sorosky
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

2.  Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.

Authors:  B Brockstein; B Samuels; R Humerickhouse; R Arietta; P Fishkin; J Wade; J Sosman; E E Vokes
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

Authors:  Robert J Morgan; Lucille Leong; Warren Chow; David Gandara; Paul Frankel; Agustin Garcia; Heinz-Josef Lenz; James H Doroshow
Journal:  Invest New Drugs       Date:  2010-10-09       Impact factor: 3.850

4.  A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Authors:  P Tang; G Roldan; P M A Brasher; D Fulton; W Roa; A Murtha; J G Cairncross; P A Forsyth
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

5.  Bryostatin-1 causes radiosensitization of BMG-1 malignant glioma cells through differential activation of protein kinase-Cδ not evident in the non-malignant AA8 fibroblasts.

Authors:  Raghubendra Singh Dagur; Shashank Hambarde; Sudhir Chandna
Journal:  Mol Cell Biochem       Date:  2014-12-04       Impact factor: 3.396

6.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

7.  A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  Deborah K Armstrong; John A Blessing; Katherine Y Look; Russell Schilder; Evelyn R Nunez
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

8.  Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Authors:  Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

9.  Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

Authors:  Noemi Kedei; Nancy E Lewin; Tamás Géczy; Julia Selezneva; Derek C Braun; Jinqiu Chen; Michelle A Herrmann; Madeleine R Heldman; Langston Lim; Poonam Mannan; Susan H Garfield; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Peter M Blumberg; Gary E Keck
Journal:  ACS Chem Biol       Date:  2013-02-01       Impact factor: 5.100

10.  Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.

Authors:  S Akinaga; K Nomura; K Gomi; M Okabe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.